Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoVax With or Without Ipilimumab in High-risk Renal Cell Carcinoma
NCT02950766Phase 1Active, not recruiting
- Start
- Mar 2019
- Primary completion
- Dec 2027
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of NeoVax in renal cell carcinoma (RCC) (2 arms). Primary endpoint: Dose-Limiting Toxicity at 49 days. Started Mar 2019; status: active, not recruiting.
02
Drugs
NeoVax
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02950766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02950766.